Medications/Weight
Tirzepatide Microdosing
Billed at the pharmacy's cost, if prescribed- A lower-dose tirzepatide program some people explore with a clinician as part of a weight goal.
- Compounded, not FDA approved.
Velri opens September 1, 2026. A prescription is not guaranteed.
Details
- GoalWeight
- FormInjectable (multi-dose vial) + syringes
- OptionsLower-dose program. Formulation and dosing individualized by the prescribing provider
- AvailabilityAvailability varies by state and pharmacy.
- CostThe pharmacy’s cost, billed separately if prescribed. Velri adds no markup.
What you pay
Safety & disclosures
The most common side effects are nausea, vomiting, diarrhea, decreased appetite, and constipation, most often around dose increases. Tirzepatide caused thyroid C-cell tumors in animal studies, and it must not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It has also been associated with pancreatitis, gallbladder disease, and kidney injury from severe dehydration, and taking it with insulin or a sulfonylurea increases the risk of low blood sugar. Do not use tirzepatide during pregnancy, and be aware it can make oral birth control pills less effective for a period after starting or increasing the dose.
Compounded medications are not FDA approved. A prescription is required, is not guaranteed, and is determined by an independent, licensed provider based on your consultation. Velri is a non-clinical company; consultations and prescriptions are provided by independent, licensed medical groups, and medications are dispensed by independent, licensed pharmacies. Medication is priced at the pharmacy cost plus one flat Velri fulfillment fee, the same on every product. This page is for general information and is not medical advice.
